SCHEMBL2293330

SCHEMBL2293330

O=C(O)N1CCN(Cc2ccc(CCOc3ccc(Cl)cc3)c(F)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.53
CYP3A4 P08684 2/20 0.53
KCNH2 Q12809 2/20 0.53
LMNA P02545 2/20 0.53
ABCB11 O95342 1/20 0.53
CYP1A2 P05177 1/20 0.53
ADRA2A P08913 1/20 0.53
CYP2D6 P10635 1/20 0.53
CHRM1 P11229 1/20 0.53
TBXA2R P21731 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
CYP2C19 P33261 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HIF1A Q16665 1/20 0.53
F10 P00742 3/20 0.49
CACNA1G O43497 1/20 0.47
HRH3 Q9Y5N1 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232545 0.86 HRH3 (0.55) DRD3CYP3A4KCNH2LMNAABCB11
SCHEMBL2234336 0.85 HRH3 (0.59) DRD3CYP3A4KCNH2LMNAABCB11
SCHEMBL2234005 0.84 HRH3 (0.55) LMNAHRH3SMN1; SMN2KDM4EALDH1A1
SCHEMBL2233345 0.83 HRH3 (0.47) LMNAF10HRH3SMN1; SMN2KDM4E
SCHEMBL2236459 0.82 HRH3 (0.57) HRH3FAAH
Hydrochloric Acid SCHEMBL2233572 0.81 DRD4 (0.47) DRD3CYP3A4KCNH2LMNAABCB11
SCHEMBL2297134 0.80 HRH3 (0.54) LMNAHRH3SMN1; SMN2MAPTMAPK1
SCHEMBL2303680 0.80 HRH3 (0.55) LMNAHRH3SMN1; SMN2KDM4EALDH1A1
SCHEMBL2234305 0.80 HRH3 (0.47) LMNAHRH3SMN1; SMN2MAPK1KDM4E
SCHEMBL2232973 0.80 KDM4E (0.53) LMNAHRH3SMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 DRD3 787/4885CYP3A4 341/4885KCNH2 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.